Challenges and advances in device-related thrombus in left atrial appendage occlusion

Area of Science:

• Cardiology
• Biomaterials Science
• Medical Devices

Background:

• Oral anticoagulation therapy (OAC) is a primary treatment for preventing stroke and embolic events in patients with atrial fibrillation (AF).
• However, bleeding risks limit OAC tolerability in many patients.
• Left atrial appendage occlusion (LAAO) devices provide an alternative stroke risk mitigation strategy for OAC-intolerant individuals.

Purpose of the Study:

• To explore the potential of advanced biomaterials, specifically fluoropolymers, to enhance the safety and efficacy of Left Atrial Appendage Occlusion (LAAO) devices.
• To address the complication of device-related thrombus formation following LAAO procedures.

Main Methods:

• Review of existing clinical data on OAC and LAAO efficacy and complications.
• Analysis of the properties of fluoropolymers as stent-coating technologies, focusing on their role in reducing thrombus formation and promoting endothelialization.
• Evaluation of the potential application of fluoropolymer coatings to LAAO devices.

Main Results:

• LAAO devices demonstrate comparable thromboembolic event protection to OAC.
• Device-related thrombus formation is a significant complication limiting LAAO safety and efficacy.
• Fluoropolymers are established for reducing thrombus and enhancing endothelialization in other implantable devices.

Conclusions:

• Improving the biocompatibility of LAAO devices is crucial for optimizing patient outcomes.
• Fluoropolymer coatings represent a promising strategy to mitigate device-related thrombus formation after LAAO.
• Further research and development focusing on fluoropolymer-coated LAAO devices may enhance their safety profile and clinical adoption.